Cardiol Therapeutics (CRDL) Share-based Compensation (2020 - 2026)

Cardiol Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Share-based Compensation rose 68.11% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 21.83% YoY) and the FY2025 annual result came in at $7.7 million, down 24.92% from the prior year.
• Share-based Compensation was $1.3 million for Q1 2026 at Cardiol Therapeutics, down from $2.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.2 million in Q3 2024 and bottomed at -$456672.1 in Q2 2022.
• A 5-year average of $1.6 million and a median of $1.3 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 167.91% — and 2024, when it jumped 303.6%.
• Cardiol Therapeutics' Share-based Compensation stood at $698362.7 in 2022, then rose by 6.52% to $743899.4 in 2023, then soared by 202.86% to $2.3 million in 2024, then retreated by 4.07% to $2.2 million in 2025, then slumped by 37.83% to $1.3 million in 2026.
• Business Quant data shows CRDL's Share-based Compensation at $1.3 million in Q1 2026, $2.2 million in Q4 2025, and $2.9 million in Q3 2025.